These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22402942)

  • 1. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
    Yau T; Wong H; Chan P; Yao TJ; Pang R; Cheung TT; Fan ST; Poon RT
    Invest New Drugs; 2012 Dec; 30(6):2384-90. PubMed ID: 22402942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
    Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
    Zhu AX; Rosmorduc O; Evans TR; Ross PJ; Santoro A; Carrilho FJ; Bruix J; Qin S; Thuluvath PJ; Llovet JM; Leberre MA; Jensen M; Meinhardt G; Kang YK
    J Clin Oncol; 2015 Feb; 33(6):559-66. PubMed ID: 25547503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
    Gabrielson A; Tesfaye AA; Marshall JL; Pishvaian MJ; Smaglo B; Jha R; Dorsch-Vogel K; Wang H; He AR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1073-9. PubMed ID: 26449224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
    Philip PA; Mahoney MR; Holen KD; Northfelt DW; Pitot HC; Picus J; Flynn PJ; Erlichman C
    Cancer; 2012 May; 118(9):2424-30. PubMed ID: 21953248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.
    Zhu AX; Kang YK; Rosmorduc O; Evans TR; Santoro A; Ross P; Gane E; Vogel A; Jeffers M; Meinhardt G; Peña CE
    Clin Cancer Res; 2016 Oct; 22(19):4870-4879. PubMed ID: 27220960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).
    Hubbard JM; Mahoney MR; Loui WS; Roberts LR; Smyrk TC; Gatalica Z; Borad M; Kumar S; Alberts SR
    Target Oncol; 2017 Apr; 12(2):201-209. PubMed ID: 27943153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
    Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
    Castellano D; Capdevila J; Sastre J; Alonso V; Llanos M; García-Carbonero R; Manzano Mozo JL; Sevilla I; Durán I; Salazar R
    Eur J Cancer; 2013 Dec; 49(18):3780-7. PubMed ID: 24012098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.
    Kaseb AO; Garrett-Mayer E; Morris JS; Xiao L; Lin E; Onicescu G; Hassan MM; Hassabo HM; Iwasaki M; Deaton FL; Abbruzzese JL; Thomas MB
    Oncology; 2012; 82(2):67-74. PubMed ID: 22327795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).
    Abou-Alfa GK; Yen CJ; Hsu CH; O'Donoghue J; Beylergil V; Ruan S; Pandit-Taskar N; Gansukh B; Lyashchenko SK; Ma J; Wan P; Shao YY; Lin ZZ; Frenette C; O'Neil B; Schwartz L; Smith-Jones PM; Ohtomo T; Tanaka T; Morikawa H; Maki Y; Ohishi N; Chen YC; Agajanov T; Boisserie F; Di Laurenzio L; Lee R; Larson SM; Cheng AL; Carrasquilo JA
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):421-429. PubMed ID: 28120036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study.
    Hsu CH; Kang YK; Yang TS; Shun CT; Shao YY; Su WC; Sandoval-Tan J; Chiou TJ; Jin K; Hsu C; Cheng AL
    Oncology; 2013; 85(1):44-52. PubMed ID: 23838576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
    Ciuleanu T; Bazin I; Lungulescu D; Miron L; Bondarenko I; Deptala A; Rodriguez-Torres M; Giantonio B; Fox NL; Wissel P; Egger J; Ding M; Kalyani RN; Humphreys R; Gribbin M; Sun W
    Ann Oncol; 2016 Apr; 27(4):680-7. PubMed ID: 26802147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
    Koeberle D; Dufour JF; Demeter G; Li Q; Ribi K; Samaras P; Saletti P; Roth AD; Horber D; Buehlmann M; Wagner AD; Montemurro M; Lakatos G; Feilchenfeldt J; Peck-Radosavljevic M; Rauch D; Tschanz B; Bodoky G;
    Ann Oncol; 2016 May; 27(5):856-61. PubMed ID: 26884590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
    Cheng AL; Kang YK; He AR; Lim HY; Ryoo BY; Hung CH; Sheen IS; Izumi N; Austin T; Wang Q; Greenberg J; Shiratori S; Beckman RA; Kudo M;
    J Hepatol; 2015 Oct; 63(4):896-904. PubMed ID: 26071796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
    Ikeda M; Shimizu S; Sato T; Morimoto M; Kojima Y; Inaba Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka T
    Ann Oncol; 2016 Nov; 27(11):2090-2096. PubMed ID: 27573564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.